ASP 4345
Alternative Names: ASP4345Latest Information Update: 09 Mar 2021
Price :
$50 *
At a glance
- Originator Astellas Pharma
- Class Antipsychotics; Nootropics
- Mechanism of Action Dopamine D1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 09 Mar 2021 No development reported - Phase-II for Schizophrenia (Adjunctive treatment) in USA (PO) (Astellas Pharma pipeline, March 2021)
- 09 Mar 2021 No development reported - Phase-II for Schizophrenia in USA (PO) (Astellas Pharma pipeline, March 2021)
- 16 Oct 2019 Astellas Pharma completes a phase II trial in Schizophrenia (Adjunctive treatment) in USA (PO) (NCT03557931)